However, underutilization of aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, glycoprotein IIb/IIIa receptor antagonists, and thrombolytic therapy has been observed in CKD patients due to concerns of bleeding risk, worsening of renal function, and comorbidities. Here, ACE is linked to chronic kidney disease.